PCM-4 mixture of polypeptides data

The Minneapolis company announced that Phase II results show enhanced quality of life (number of opportunistic infections, wasting) in 68 patients in the first year of the three-year trial, without concurrent use of antivirals.

Markers of immune function, such as CD4 and CD8 counts, and p24 antigen, were stabilized in more than 50 percent of patients. ...